We are live on ! Find out more
ALT icon

Altimmune

29 hedge funds and large institutions have $5.1M invested in Altimmune in 2020 Q1 according to their latest regulatory filings, with 12 funds opening new positions, 4 increasing their positions, 4 reducing their positions, and 8 closing their positions.

New
Increased
Maintained
Reduced
Closed

117% more call options, than puts

Call options by funds: $968K | Put options by funds: $447K

109% more capital invested

Capital invested by funds: $2.44M → $5.1M (+$2.67M)

50% more first-time investments, than exits

New positions opened: 12 | Existing positions closed: 8

4% more funds holding

Funds holding: 2829 (+1)

1.88% more ownership

Funds ownership: 8.46%10.34% (+1.9%)

0% more repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 4

Holders
29
Holders Change
+1
Holders Change %
+3.57%
% of All Funds
0.64%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
12
Increased
4
Reduced
4
Closed
8
Calls
$968K
Puts
$447K
Net Calls
+$521K
Net Calls Change
+$463K

ALT Hedge Fund Activity: Q1 2020 in Review

29 of the 4,539 institutional investors tracked by Wall St. Rank reported a position in Altimmune (ALT) for Q1 2020, worth a combined $5.1M — up 109% from $2.44M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new ALT positions and 8 closed out — a net gain of 4 holders — while 4 added to existing stakes and 4 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $1.02M. The largest seller was Sabby Management, exiting entirely with an estimated $103K sold.

  • 29 institutional investors held Altimmune (ALT) as of Q1 2020, up from 28 in Q4 2019.
  • Funds reported $5.1M of Altimmune stock for Q1 2020, up 109% quarter-over-quarter.
  • 12 funds opened new Altimmune positions in Q1 2020 and 8 closed out, a net change of +4 holders.
  • The largest Altimmune buyer in Q1 2020 was Renaissance Technologies, an estimated $1.02M added.
  • The largest Altimmune seller in Q1 2020 was Sabby Management, an estimated $103K sold.

Based on aggregated 13F filings for Q1 2020.